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Lessons From the
Learning Curve*
Peter C. Block, MD
Atlanta, Georgia
Transcatheter aortic valve insertion (TAVI) has taken cen-
ter stage, but TAVI is not easy to do, has limitations, and is
a complex procedure requiring multiple operators. Thus,
interventional cardiologists, cardiac surgeons, echocardiog-
raphers, anesthesiologists, and vascular surgeons have
formed “teams” that come together to work in hybrid
operating rooms or catheterization laboratories to perform
TAVI in what have been selected investigational centers in
the United States. Published results of the first U.S. trial
and, of course, multiple reports from European centers,
which have had the opportunity of using TAVI for far
longer, have uniformly supported the notion that TAVI is
successful therapy for selected patients. But there is no free
lunch—TAVI has associated risks of stroke, vascular com-
plications, heart block, and so on. So, the questions are
“How difficult is TAVI really?”; “How does experience with
TAVI influence risk?”; and “With experience, does TAVI
become ‘easy’ enough so that it can be performed by large
numbers of practitioners?” In short, “What is the learning
curve for this procedure?”
See page 72
In this issue of JACC: Cardiovascular Interventions, re-
searchers from the Mayo Clinic report on “Transcatheter
Aortic Valve Implantation: Assessing the Learning Curve”
(1), which begins to give us some insight into the answers.
The analysis of data from 44 patients does not tell us about
patient outcomes but does give us considerable insight into
the TAVI procedure itself. Patients were divided into early,
mid, and latest tertiles. Since each tertile had only 14 or 15
patients, percentage differences in baseline characteristics
between tertiles are not meaningful, though the uniformity
of the echocardiographic variables across tertiles indicates
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irectFlow Medical.that patients were similar. The most intriguing part of the
report shows scatter plots of contrast volume, fluoroscopy
time, and time from valvuloplasty to valve deployment
versus patient number. In their report, as TAVI experience
increases, there are smaller variable ranges, with a “smooth-
ing” of the curve. The operators at Mayo became progres-
sively “better” at doing the TAVI procedure, and the
authors conclude that it takes about 30 cases to achieve
proficiency. Significant decreases in median contrast vol-
ume, valvuloplasty to valve deployment time, and fluoros-
copy time occurred from the first to third tertile. Intertertile
30-day outcomes are not different, and the implication of
decreased complications over time is not shown by their
data. A recent report from the Vancouver, BC, group (2)
showed improvement in TAVI 30-day mortality with in-
creasing experience, but arguably this was due to better case
selection rather than to operators being more proficient with
the procedure.
Aside from the information that operators doing TAVI
need about 30 cases to become “better,” I feel that there is
an additional message in the Mayo report. The data allow a
peek into the near future that may be either troubling, or
not. The Edwards Sapien transcatheter valve (Edwards
Lifesciences, Irvine, California) was given Food and Drug
Administration (FDA) approval for treatment of selected
nonoperative candidates with aortic stenosis, on November 2,
2011. The Mayo data should add fuel to the fire of what
happens now. If it takes 30 cases to achieve procedural
proficiency and ultimately that relates to patient outcomes,
we should consider what might happen. The number of
sites that plan on performing TAVI now that a device is
FDA-approved is unknown. Projections have been as high
as 4 or 5 new sites per state. With approximately 100 sites
already doing TAVI in the United States, the total number
of sites performing TAVI will be around 350. If that
number holds up, around 7,500 patients will be part of the
learning curve as additional site operators become “profi-
cient.” That also assumes that becoming “proficient” is not
influenced by the time span in which those 30 learning-
curve patients per site actually have their TAVI. In addition,
we know nothing about how proficiency, once achieved, will
be maintained—particularly by low-volume operators. If
there were innumerable TAVI candidates out there for the
proposed TAVI sites, it would not be an issue, but there are
not. Estimates of how many total patients might undergo
TAVI once a device is approved is fraught with error, but
25,000 to 30,000 patients per year (at least for the first few
years after approval) seems reasonable. If 1 or possibly 2 sites
per state continue as high-volume sites (100 cases/year),
those 100 sites will account for at least 10,000 cases per year.
That leaves about 15,000 cases to be divided among 200
sites (or 75 cases/year/site), but it is highly unlikely that
distribution of patients among sites will be equal. Some sites
will do more, and many will do fewer cases. Assuming 2
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81operators need to be “competent” per site, an operator will
do 1 case/week in a best-case scenario, but many sites will
have TAVI volumes far lower. Is this acceptable and safe?
Designation of “inoperable” patients, which will likely be
mandated by the FDA as appropriately treated with TAVI
(at least for now), will be strict and further limit patient
accessibility as will the presence of peripheral vascular
disease, which may decrease potential patient numbers
further. If one now returns to the Mayo “Learning Curve”
data (1) for procedure proficiency, under this scenario, it
may take more than a full year for an operator to become
procedure “proficient.” The question of maintenance of
proficiency is totally unanswered at present.
So what does all this boil down to? The FDA, the Society
of Thoracic Surgeons, and the American College of Cardi-
ology have all supported limiting the number of U.S.
centers, center certification, minimum volume require-
ments, and operator credentialing. There will clearly be
tension between centers that are already doing TAVI and
those that simply cannot be credentialed—causing a have/
have-not environment. How all this will play out over the
next year should concern every center and operator contem-
plating the addition of TAVI to their list of available
therapies. My feeling is that many centers that would like to
do TAVI now that a device is approved will quickly recognize vthat putting together the personnel and facilities is only a first
step. Doing TAVI well is a second hurdle, as pointed out by
the Mayo paper. Third, caring for complex patients with aortic
stenosis and multiple comorbidities is labor intensive, resource
rich, and time consuming. Lastly, whether reimbursement for
TAVI will even begin to cover the cost of the enterprise
remains to be seen. TAVI may well be a center-stage diva, but
it is also a jealous, high-maintenance mistress. It should be an
interesting roll out.
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